Extending life in late-stage prostate cancer, but extending quality of life too

An article in the April issue of Lancet Oncology has provided additional data from the randomized, double-blind Phase III PREVAIL trial of enzalutamide versus placebo in men with asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Long-term survival of hormone-naive patients in biochemical failure post-surgery

A new paper in the European Journal of Nuclear Medicine and Molecular Imaging provides some interesting data on the long-term survival of men with progressive prostate cancer after initial treatment by radical prostatectomy. … READ MORE …

Survival times among men with biochemically recurrent prostate cancer

It would hardly come as a shock to most experienced prostate cancer advocates and patients to learn that there is an association between survival time and the aggressiveness of a patient’s cancer at the time of diagnosis if that cancer progresses. … READ MORE …

The EMBARK trial in men with progressive but non-metastatic prostate cancer

We apparently managed to miss providing readers with information about initiation of what may be a game-changing, randomized, Phase III, trial in the treatment of progressive prostate cancer. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

CTC count as a biomarker for response to chemotherapy in men with mCRPC

There is increasing evidence that circulating tumor cell (CTC) count may be important in assessing the likelihood for an optimal response to treatment with docetaxel-based chemotherapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

New global data on 5-year prostate cancer survival

A new study by Allemani et al., just published in The Lancet, has provided us with data from the largest ever global study of cancer survival, encompassing nearly 26 million people in 279 population-based registries from 67 countries around the world. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,270 other followers